Noteworthy - Pharmaceutical Executive

ADVERTISEMENT

Noteworthy

Manufacturers Struggle with FDA's "Breakthrough Drug" Development

March 21, 2014

Accelerated testing and production create challenges in documenting product quality, writes Jill Wechsler.

Population Health: The Call to Community

March 11, 2014

Population health is the foundation for much of what is truly new in US health reform. Pharm Exec talks to Dr. David Nash, Dean of the Jefferson Medical University School of Population Health.

What Do Pharma's "High Performers" Have in Common?

March 7, 2014

A study of high-performing pharma companies reveals science-based innovation strategies and patient-outcome-based commercial models are now the key drivers of growth.

The New Metrics of Market Success

March 3, 2014

Profitability now depends on metrics to help companies answer a key strategic question: "stay the course" with more investment in sales and marketing? Or "stand down" and deploy those scarce assets somewhere else?

Pharm Exec: Annual Press Audit 2014

March 3, 2014

Pharm Exec's latest survey of press issues shows that media coverage continues to remain on balance negative toward the industry, by a slight margin: 47% this year compared to a 46% average over the last seven years.

The Push for Transparency: Risks, Costs, and Concerns

February 26, 2014

The growing clamor for broader access to information on health care practices, policies and costs is affecting research, marketing and compliance, writes Jill Wechsler.

What Would Britain's EU Exit Mean for Drugmakers?

February 25, 2014

The possibility of a future "Brexit" — a British exit from the EU — has been exercising the world of medicines, writes Peter O'Donnell.

Pharm Exec Global Digest — Sales & Marketing Special

February 12, 2014

In the latest issue of PEGD: Face-to-Face Meetings in the Digital Age; the US Rx Rep in the Obamacare Era; the Future of the iPad — And more

Innovation and Market Growth in Brazil

February 10, 2014

Brazil is the first Latin American country to emerge as a global biopharmaceutical collaborator. Hellen Berger reports.

ADVERTISEMENT

Click here